Analyst Research Roundup: Concert Pharmaceuticals, Inc. (CNCE), Fossil Group, Inc. (FOSL)

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) tinted gains of +2.18% (+0.28 points) to US$13.12. The volume of 0.29 Million shares climbed down over an trading activity of 221.32 Million shares. EPS ratio determined by looking at last 12 month figures is -2.39. Over the same time span, the stock marked US$21.84 as its best level and the lowest price reached was US$10.8. The corporation has a market cap of US$323.54 Million.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)’s earnings per share has been growing at a -33 percent rate over the past 5 year when average revenue increase was noted as -16.2 percent. The return on equity ratio or ROE stands at -29.3 percent while most common profitability ratio return on investment (ROI) was -33.3 percent. The company’s institutional ownership is monitored at 75.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.83. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Fossil Group, Inc. (NASDAQ:FOSL) is worth US$741.32 Million and has recently risen 2.18% to US$14.53. The latest exchange of 1.35 Million shares is below its average trading activity of 1.75 Million shares. The day began at US$14.2 but the price moved to US$13.98 at one point during the trading and finally capitulating to a session high of US$14.56. The stock tapped a 52-week high of US$32.17 while the mean 12-month price target for the shares is US$13.8.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.23, and a price to sales ratio of 0.29. For the past 5 years, the company’s revenue has grown -4.9%, while the company’s earnings per share has grown -15%. With an institutional ownership near 0%, it carries an earnings per share ratio of -0.09.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 2 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.2.